HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin : an association with glucose-lowering effects

フルテキスト
64_EJ16-0295.pdf657.05 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/68415

タイトル: Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin : an association with glucose-lowering effects
著者: Takase, Takahiro 著作を一覧する
Nakamura, Akinobu 著作を一覧する
Miyoshi, Hideaki 著作を一覧する
Yamamoto, Chiho 著作を一覧する
Atsumi, Tatsuya 著作を一覧する
キーワード: Fatty liver
Ipragliflozin
発行日: 2017年 3月
出版者: The Japan Endocrine Society
誌名: Endocrine Journal
巻: 64
号: 3
開始ページ: 363
終了ページ: 367
出版社 DOI: 10.1507/endocrj.EJ16-0295
抄録: In this study, we investigated the ameliorating effects of ipragliflozin on fatty liver in patients with type 2 diabetes. The factors that influenced the amelioration of fatty liver were also examined. Analysis included data of 21 Japanese patients with type 2 diabetes obtained from our prospective observational study. After obtaining patients' informed consent, once-daily ipragliflozin (50 mg/day) was given for 16 weeks. In addition to several clinical parameters, body composition was also compared before and after 16 weeks of treatment. The extent of fatty liver was estimated using a fatty liver index (FLI). After 16 weeks, FLI significantly decreased, from 70.1 ± 19.4 to 60.3 ± 25.5 (p = 0.0009) as well as levels of fasting plasma glucose (FPG), HbA1c, body weight, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and fat mass. To reveal the factors influencing the FLI changes observed on ipragliflozin treatment, correlations between changes in FLI and several other measured parameters were examined. Changes in FPG (correlation coefficient = 0.4683, p = 0.0323) and HbA1c (correlation coefficient = 0.4383, p = 0.0469) showed significant positive correlations with changes in FLI. On the other hand, no correlations of changes in FLI were observed with body weight, VAT, SAT nor fat mass. In conclusion, ipragliflozin ameliorated FLI in Japanese patients with type 2 diabetes. Improvement in FLI was associated with that of glucose intolerance.
資料タイプ: article
URI: http://hdl.handle.net/2115/68415
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 三好 秀明

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学